CurveBeam AI has raised A$1.75 million through an oversubscribed SPP shortfall offer and placement, lifting its recent capital raised to A$7.36 million. The funds will support the HiRise China launch, product development, supply-chain preparation and working capital.
- A$1.75m raised at A$0.018 per share
- A$1.39m secured through the SPP shortfall offer
- Further A$360,000 placed after demand exceeded available capacity
- A$7.36m raised across the company’s recent funding program
- Proceeds earmarked for HiRise China expansion and development
Oversubscribed offer adds A$1.75 million
CurveBeam AI Limited (ASX:CVB) has secured more capital than its original SPP capacity could accommodate, raising A$1.75 million from Australian and international investors at A$0.018 a share. The package comprises A$1.39 million through the SPP shortfall offer and a further A$360,000 placement at the same price.
Demand exceeded the available placement capacity, prompting the company to scale back applications. The result gives CurveBeam an additional funding buffer as it prepares to take its HiRise specialised CT scanner into China, although the new shares will also add to the company’s issued capital.
Recent fundraising reaches A$7.36 million
The latest raise brings total funds generated through the recent placement, SPP and shortfall process to A$7.36 million. That total includes a A$5 million placement priced at A$0.02 a share, A$606,150.70 raised under the SPP, and the latest A$1.75 million raised at the discounted SPP price.
The SPP itself issued 33,675,039 shares for A$606,150.70, compared with the 111,111,111 shares that could have been issued if the offer had reached its maximum capacity. The company has not disclosed the final number of shares to be issued under the shortfall offer and additional placement.
China launch sits at centre of spending plan
CurveBeam says the capital will fund sales and marketing activity for the HiRise China launch, research and development including product enhancements, supply-chain preparation and working capital. The announcement does not provide a timetable for the launch or quantify the expected contribution from China.
Chief executive Greg Brown said the company was progressing commercial opportunities in China, the United States and other international markets. He also pointed to the FDA 510(k) clearance of CurveBeam’s CT-based bone mineral density technology earlier in the week, describing it as a regulatory foundation for integrating bone-quality assessment into its weight-bearing and existing supine CT platforms.
Commercial execution becomes the next test
The fundraising removes an immediate financing question, but shifts attention to execution: how quickly CurveBeam can convert the enlarged capital pool into a China launch, product enhancements and commercial opportunities. Investor demand was strong enough to exceed the available capacity, yet the announcement offers no new revenue guidance or cash-runway estimate.
The next useful markers will be completion and quotation of the shortfall and placement shares, evidence of progress toward the HiRise China launch, and updates on the commercial use of the newly raised funds. The regulatory milestone broadens the company’s stated technology ambitions, but its financial value will depend on whether those ambitions become paid clinical or imaging deployments.
Bottom Line?
CurveBeam has strengthened its funding position, but the investment case now turns on launch progress, commercial conversion and how efficiently the A$7.36 million pool is deployed.
Questions in the middle?
- When will CurveBeam complete and quote the shortfall and placement shares?
- What specific commercial milestones will mark the HiRise China launch?
- How quickly can the newly cleared bone mineral density technology contribute to revenue?